Aug 2, 2022 7:30 am EDT Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
Aug 1, 2022 7:00 am EDT Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
May 18, 2022 7:30 am EDT Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
Mar 2, 2022 7:30 am EST Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
